Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure
2023; American Medical Association; Volume: 330; Issue: 22 Linguagem: Inglês
10.1001/jama.2023.23204
ISSN1538-3598
AutoresMandeep R. Mehra, Ivan Netuka, Nir Uriel, Jason N. Katz, Francis D. Pagani, Ulrich P. Jorde, Finn Gustafsson, Jean M. Connors, Peter Ivák, Jennifer Cowger, John Ransom, Aditya Bansal, Koji Takeda, Richa Agarwal, Mirnela Byku, Michael M. Givertz, Abbas Bitar, Shelley Hall, Daniel Zimpfer, J. David Vega, Manreet Kanwar, Omar Saeed, Daniel J. Goldstein, Rebecca Cogswell, Farooq H. Sheikh, Matthew Danter, Yuriy Pya, Anita Phancao, John Henderson, D. Crandall, Kartik S. Sundareswaran, Edward G. Soltesz, Jerry D. Estep, Scott Silvestry, Antone Tatooles, Nasir Siulemanjee, Brett C. Sheridan, Sanjeev Gulati, Eugene S. Chung, Clément Delmas, Carmelo A. Milano, Pierre Dos Santos, Pavan Atluri, Douglas Horstmanshof, David A. D’Alessandro, Sriram Nathan, Peter Eckman, Anelechi Anyanwu, Anna Mara Scandroglio, Alessandro Ortalda, Ezequiel Molina, Jacob Abraham, Hoong Sern Lim, Robert Adamson, Ashwin Ravichandran, Chris Hayward, William Hiesinger, John W. Entwistle, Jennifer Conway, Eric Adler, Jonathan Grinstein, Andreas Brieke, Mary Keebler, Jeffrey D. Alexis, Igor Gošev, Craig H. Selzman, David M. Kaye,
Tópico(s)Heart Failure Treatment and Management
ResumoLeft ventricular assist devices (LVADs) enhance quality and duration of life in advanced heart failure. The burden of nonsurgical bleeding events is a leading morbidity. Aspirin as an antiplatelet agent is mandated along with vitamin K antagonists (VKAs) with continuous-flow LVADs without conclusive evidence of efficacy and safety.
Referência(s)